octreotide infusion duration
Reading File
Finding Sources
Searching the Web
octreotide infusion duration clinical indications variceal bleeding
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Searching PubMed
octreotide infusion duration variceal hemorrhage
Here is a comprehensive summary of octreotide infusion duration across its major clinical indications:
Octreotide Infusion Duration
1. Esophageal/Gastric Variceal Hemorrhage (primary indication)
Dose: 50 µg IV bolus → 50 µg/h continuous infusion
Duration: 2–5 days (most guidelines cite 5 days as standard)
- Initiated as soon as variceal bleeding is suspected, before endoscopy
- Continued after endoscopic band ligation (EBL) or sclerotherapy as adjunct therapy
- Goodman & Gilman's states: "50-µg bolus dose followed by 50 µg hourly for 2–5 days"
- Yamada's Gastroenterology and Current Surgical Therapy both specify 5 days as the target duration
- Octreotide does not cause a sustained decrease in portal pressure (its benefit is additive to endoscopic therapy, not independent)
Note on duration controversy: A 2025 RCT (Allam et al., LOVARB trial) compared 24-hour vs. 72-hour infusion post-EBL. Current guidelines still recommend 2–5 days, but this is an area of active investigation. The optimal duration after successful endoscopic control is not firmly established.
2. Pediatric Variceal Bleeding
Dose: 1–2 µg/kg bolus (up to 50 µg) → 1–2 µg/kg/h infusion, titrated up to 4 µg/kg/h
Duration: Continue until bleeding stops; no fixed pediatric duration defined — managed in ICU with ongoing monitoring — Tintinalli's Emergency Medicine
3. Carcinoid Crisis (perioperative)
Indication: Patients with carcinoid syndrome/neuroendocrine tumors undergoing surgery
- Preoperative: admission for IV octreotide infusion or large-dose administration before anesthetic induction
- Intraoperative: ongoing high-dose octreotide infusion for cardiovascular instability
- Postoperative: weaned gradually in the postoperative period (no fixed duration — titrated to symptoms/hemodynamics)
- For acute carcinoid crisis: IV bolus + continuous infusion + corticosteroids + vasopressors as needed — Sabiston Textbook of Surgery
4. Hepatorenal Syndrome (HRS)
Used as subcutaneous octreotide (not infusion) in combination with midodrine and albumin — less effective than terlipressin + albumin for reversing HRS — Comprehensive Clinical Nephrology, 7th ed.
Quick Reference Table
| Indication | Bolus | Infusion Rate | Duration |
|---|---|---|---|
| Variceal hemorrhage (adult) | 50 µg IV | 50 µg/h | 2–5 days |
| Variceal hemorrhage (pediatric) | 1–2 µg/kg (max 50 µg) | 1–4 µg/kg/h | Until bleeding stops |
| Carcinoid crisis (periop) | IV bolus | High-dose infusion | Weaned postoperatively |
| Carcinoid crisis (acute) | IV bolus | Continuous | Titrated to response |
Key points:
- The 5-day duration for variceal bleeding is the most cited standard (Yamada's, Current Surgical Therapy), though 2–5 days is acceptable per Goodman & Gilman's
- The 2025 LOVARB trial is actively examining whether shorter infusions (24–72 h) post-EBL are non-inferior
- Hyperglycemia is the main adverse effect requiring glucose monitoring during infusion
- In the US, octreotide is preferred over vasopressin; terlipressin (where available) is the only agent shown to independently reduce mortality
This is a shared conversation. Sign in to Orris to start your own chat.